Literature DB >> 10759907

Spinal cord infarction during use of zolmitriptan: a case report.

N Vijayan1, J H Peacock.   

Abstract

A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan. The partial lesion of the cord at T7 predominantly involved the spinothalamic pathways on the left side. Clinical features suggested that the lesion was an ischemic infarct, and this was confirmed by an MRI scan. There were no other known risk factors for vascular disease. There has been mild improvement of her symptoms, but most of the symptoms did not resolve. There are isolated case reports of stroke secondary to the use of triptans, however, this is the first case of spinal cord infarction reported following the use of this group of drugs. The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759907     DOI: 10.1046/j.1526-4610.2000.00012.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  5 in total

Review 1.  The risk of stroke in patients with migraine and implications for migraine management.

Authors:  Gretchen E Tietjen
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Migrainous infarction: aspects on risk factors and therapy.

Authors:  Katarina Laurell; Erik Lundström
Journal:  Curr Pain Headache Rep       Date:  2012-06

3.  Renal infarct: a rare disease due to a rare etiology.

Authors:  Divya Akshintala; Saurabh K Bansal; Vamsi Krishna Emani; Manajyoti Yadav
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-06-15

4.  Bilateral Renal Infarctions During the Use of Sumatriptan.

Authors:  Blaise Abramovitz; Amanda Leonberg-Yoo; Jehan Z Bahrainwala; Harold Litt; Michael R Rudnick
Journal:  Kidney Int Rep       Date:  2018-05-16

Review 5.  The Migraine-Stroke Connection.

Authors:  Mi Ji Lee; Chungbin Lee; Chin-Sang Chung
Journal:  J Stroke       Date:  2016-05-31       Impact factor: 6.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.